Roth Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $19

Benzinga Newsdesk www.benzinga.com Neutral 58.9%

Neg 0% Neu 58.9% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Buy rating and announces Price Target of $19.